Bioventus Inc.

BVSNASDAQHealthcare● Active

$8.95

$-0.09(-1.00%)

Market Cap$606345030

P/E Ratio—

52W High$11.249

52W Low$5.81

Avg Volume552K

Open$9.09

Beta0.67

Overview

Bioventus Inc. (BVS) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BVS · free cash flow · updated Jun 8, 2026

Core FCF metrics

BVS · FCF · TTM · margin & CAGR

Free cash flow was $71.4M for FY2025 (fiscal year ending 2025-12-31), up 89.0% year-over-year The FCF margin was 12.6%. Five-year CAGR stands at +6.9%.

FY2025 Free Cash Flow$71.4M▲ +89.0% YoY

Trailing 12M (TTM)$100.6Mtrailing 4 quarters sum

FCF Margin12.6%$71.4M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGR+6.9%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BVS · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$74.0M(3M)$71.4M▲ +89.0%12.6%

FY2024$38.8M(1M)$37.8M▲ +373.4%6.6%

FY2023$15.3M(7M)$8.0M▲ +153.2%1.6%

FY2022−$13.5M(1M)−$15.0M▼ 814.7%-2.9%

FY2021$23.0M(21M)$2.1M▼ 95.9%0.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BVS · P/FCF · FCF yield · FCF per share

Bioventus Inc. (BVS) trades at a FCF yield of 16.57% and a price-to-free-cash-flow ratio of 5.9x. FCF per share stands at $1.51, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

16.57%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.51

TTM FCF ÷ Shares Outstanding

Price / FCF

x5.9

Share Price ÷ FCF per Share

EV / FCF (TTM)

x5.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BVS · cash flow statement · operating / investing / financing

For FY2025, Bioventus Inc. generated $74.0M in operating cash flow and spent 3M in capital expenditures, yielding $71.4M in free cash flow.

Operating Activities

+$74.0M

Cash from core business operations

2025-12-31

Investing Activities

−$3.2M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$61.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($74.0M) − |CapEx| (3M) = FCF ($71.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BVS vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Bioventus Inc.YOU

BVS

$71.4M+89.0%12.6%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Bioventus Inc. (BVS) reported free cash flow of $71.4M for FY2025 (fiscal year ending 2025-12-31), up 89.0% year-over-year. The FCF margin was 12.6%.

Based on available data, Bioventus Inc. has maintained positive free cash flow for at least 8 fiscal year(s). FCF peaked at $71.4M in FY2025. The 5-year CAGR stands at +6.9%.

Bioventus Inc.'s FCF yield is 16.57% and price-to-FCF ratio is 5.9x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BVS free cash flow · 8 questions

Bioventus Inc. free cash flow was $71.4M for FY2025, up 89.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $100.6M.

BVS free cash flowBVS FCFBVS FCF 2025BVS free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Bioventus Inc. · Bioventus Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026